RPG Life Sciences Reports Strong Q2 FY26 Results with 7.6% Q-o-Q Revenue Growth
RPG Life Sciences reported Q2 FY26 revenue up 7.6% Q-o-Q to ₹181.7 crore, with EBITDA margin at 24.0%. Domestic formulations outperformed the market.
The announcement details solid quarterly financial performance with positive growth indicators and a confident management outlook. This indicates consistent operational strength and positive business momentum for the company, making it a moderately impactful update for investors.
The company reported healthy revenue growth both quarter-on-quarter and year-on-year, maintaining a strong EBITDA margin. The domestic formulations business significantly outpaced the market, and management expressed a positive outlook on strategic execution and future growth.
RPG Life Sciences Limited announced its unaudited financial results for the second quarter and half year ended September 30, 2025: * Q2 FY26 Revenue from operations increased by 7.6% quarter-on-quarter to ₹181.7 crore, up from ₹168.9 crore. Year-on-year, revenue grew by 5.5% from ₹172.2 crore. * EBITDA margin for Q2 FY26 stood at a strong 24.0%. * For H1 FY26, revenue grew by 3.8% year-on-year to ₹350.6 crore, compared to ₹337.6 crore.
Mr. Ashok Nair, Managing Director, commented on the results and business outlook: * The company strengthened its growth trajectory through disciplined execution and clear strategic focus. * The domestic formulations business delivered market-beating performance, growing 13.5% in H1 FY26 against the Indian Pharma Market's 7.4% growth. * International Formulations and API businesses are progressing steadily due to new customer acquisitions, expansion into emerging and regulated markets, and new molecule launches. * The company remains committed to building a future-ready pharmaceutical enterprise focused on innovation, patient happiness, a people-first culture, and sustainable value delivery.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.